Press releases

5 May, 2020

Regulatory

NeuroVive publishes outcome in rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company ...

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...

19 February, 2020

Regulatory

NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333

Lund, Sweden, 19 February 2020, NeuroVive Pharmaceutical AB (Nasdaq Stockholm) today announced that the Board of Directors of NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has reso ...

7 March, 2019

Regulatory

NeuroVive receives SEK 28.2 Million in a directed new share issue

Lund, Sweden, 7 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue of shares, which has rais ...

11 February, 2019

Regulatory

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares ...

22 January, 201919 February, 2024

Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

Lund, Sweden, 22 January 2019 – NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the prospectus in connection with NeuroVive Pharmaceutical AB’s (publ) (“N ...

10 December, 2018

Regulatory

NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report

Lund, Sweden, 10 December 2018 - NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "t ...

10 December, 2018

Regulatory

Outcome of the Exercise of Warrants in NeuroVive

Lund, Sweden, 10 December 2018 –NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or “the Company”) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announces the outcome of the exercise of warrants of serie ...

27 April, 2018

Regulatory

Preferential rights issue in NeuroVive oversubscribed

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...

15 February, 2018

Regulatory

NeuroVive decides on a Rights issue for continued drug development

Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "th ...

3 November, 2017

Regulatory

NeuroVive conducts a directed new share issue of SEK 5.3 Million

Lund, Sweden, 3 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directe ...

10 May, 2016

Regulatory

NeuroVive preferential rights issue fully subscribed

NeuroVive Pharmaceutical AB (publ) has completed the preferential rights issue of units, comprising shares and warrants, authorized by the Extraordinary General Meeting on 31 March 2016. The preferent ...